Neurotechnology startup Mave Health has secured $2.1 million (approximately ₹18 crore) in a seed funding round led by Blume Ventures, with additional investment from Inuka Capital, Stanford Angels, Aureolis Ventures, All In Capital, and several notable angel investors. This funding highlights the growing overlap between deep technology and the direct-to-consumer (D2C) market in India, signaling a new stage in the development of wellness-focused D2C startups.
Founded in 2023 by Dhawal Jain, Jai Sharma, and Aman Kumar, Mave Health is positioning itself uniquely in the Indian D2C landscape by offering non-invasive wearable headsets aimed at enhancing focus, mood, and stress management. The company combines neuroscience with consumer technology to introduce a novel segment within D2C electronics and wellness products.
The capital raised is intended to support the company’s plans for expanding its D2C presence, including launching its wearable headset across India and the United States, and scaling manufacturing operations. This approach aligns with emerging trends for 2025, where startups prioritize global-first strategies and product-driven growth within the Indian D2C sector.
Mave Health’s primary device uses transcranial direct current stimulation (tDCS) to engage the prefrontal cortex during 20-minute daily sessions. The lightweight headset, weighing around 100 grams, provides low-intensity electrical stimulation to brain areas linked to attention and emotional regulation, exemplifying a scientifically grounded product launch within the D2C electronics space.
Initial market response suggests strong consumer interest in India’s D2C mental wellness segment. The product has sold out three limited production batches within 36 hours, and its launch video has generated over one million impressions, demonstrating the effectiveness of influencer marketing and digital storytelling in this space.
With a beta user base exceeding 500 individuals, the company reports promising outcomes: 80% of users noted productivity improvements over 60%, 75% experienced stress reductions above 50%, and mood scores improved by an average of 77%. These results support the company’s revenue growth potential and reinforce its position among the fastest-growing D2C brands in the neurotechnology category.
Mave Health’s companion app enables users to track sessions, tailor treatment protocols, and monitor progress while preserving privacy by not collecting sensitive brain data. This reflects a sophisticated D2C strategy that blends product design with consumer trust.
The company plans to begin shipments in April 2026, demonstrating operational readiness and alignment with supply chain innovations suited for the D2C model. Its omnichannel approach, which includes pre-orders and caters to global demand, aligns with broader shifts toward cross-border expansion and integrated sales channels within the D2C market.
From an investment standpoint, this round indicates strong confidence in deeptech D2C startups that address significant consumer needs. As India’s early-stage funding ecosystem for premium D2C brands evolves, companies like Mave Health are influencing the sector’s future direction.
Mave Health’s progress offers insight into current developments in India’s D2C industry, where innovation, scientific research, and consumer demand intersect. The startup distinguishes itself as a pioneering player, moving beyond traditional wellness categories in the Indian market.
Supported by reputable investors and driven by scientific research, Mave Health is emerging as a notable contender within the Indian D2C ecosystem, reshaping consumer approaches to mental performance, productivity, and everyday wellness in this evolving landscape.
